SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 232 filers reported holding SAGE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $227,201 | -88.5% | 4,832 | -89.7% | 0.00% | -83.3% |
| Q1 2023 | $1,975,603 | +92.6% | 47,083 | +75.1% | 0.01% | +100.0% |
| Q4 2022 | $1,025,699 | -80.9% | 26,893 | -80.3% | 0.00% | -83.3% |
| Q3 2022 | $5,359,000 | -5.8% | 136,853 | -22.3% | 0.02% | -5.3% |
| Q2 2022 | $5,686,000 | +2620.6% | 176,025 | +2685.6% | 0.02% | +1800.0% |
| Q1 2022 | $209,000 | -98.1% | 6,319 | -95.8% | 0.00% | -96.6% |
| Q1 2021 | $11,287,000 | -0.8% | 150,794 | +14.7% | 0.03% | -12.1% |
| Q4 2020 | $11,375,000 | +154.8% | 131,493 | +80.0% | 0.03% | +106.2% |
| Q3 2020 | $4,464,000 | -71.5% | 73,044 | -80.6% | 0.02% | -79.5% |
| Q2 2020 | $15,687,000 | +14.0% | 377,279 | -21.2% | 0.08% | -30.4% |
| Q1 2020 | $13,758,000 | +1586.0% | 479,025 | +4138.0% | 0.11% | +5500.0% |
| Q4 2019 | $816,000 | -85.5% | 11,303 | -87.5% | 0.00% | -90.0% |
| Q3 2017 | $5,644,000 | +102.4% | 90,596 | +137.2% | 0.02% | +53.8% |
| Q2 2015 | $2,788,000 | – | 38,186 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |